Fetzima patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8865937 ALLERGAN Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
May, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43879 ALLERGAN Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
Jan, 2026

(2 years from now)

US8481598 ALLERGAN Stable dosage forms of levomilnacipran
Mar, 2031

(7 years from now)

Fetzima is owned by Allergan.

Fetzima contains Levomilnacipran Hydrochloride.

Fetzima has a total of 3 drug patents out of which 0 drug patents have expired.

Fetzima was authorised for market use on 25 July, 2013.

Fetzima is available in capsule, extended release;oral dosage forms.

Fetzima can be used as treatment of major depressive disorder (mdd).

The generics of Fetzima are possible to be released after 23 May, 2032.

Drug Exclusivity Drug Exclusivity Expiration
M (M) Oct 7, 2022

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Treatment of major depressive disorder (mdd)


How can I launch a generic of FETZIMA before it's drug patent expiration?
More Information on Dosage

FETZIMA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic